THE ROLE OF SECONDARY BILE ACID ON A DECREASE IN HEPATIC CYTOCHROME P450 3A EXPRESSION LEVEL BY CIPROFLOXACIN

被引：0
|
作者：
Toda, T. [1 ]
Hotta, A. [1 ]
Ishii, M. [1 ]
Okaniwa, T. [1 ]
Ikarashi, N. [1 ]
Ochiai, W. [1 ]
Sugiyama, K. [1 ]
机构：
[1] Hoshi Univ, Dept Clin Pharmacokinet, Tokyo 142, Japan
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2011年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [31] Induction of hepatic cytochrome P450 2B and P450 3A isozymes in rats by zolazepam, a constituent of Telazol(R)
    Wong, A
    Bandiera, SM
    BIOCHEMICAL PHARMACOLOGY, 1998, 55 (02) : 201 - 207
  • [32] Cytochromes P450 .6. Constitutive expression of hepatic cytochrome P450 genes
    Gonzalez, FJ
    Lee, YH
    FASEB JOURNAL, 1996, 10 (10): : 1112 - 1117
  • [33] The Gut as a Barrier to Drug AbsorptionCombined Role of Cytochrome P450 3A and P-Glycoprotein
    Yuanchao Zhang
    Leslie Z. Benet
    Clinical Pharmacokinetics, 2001, 40 : 159 - 168
  • [34] Interaction of cytochrome P450 3A inhibitors with P-glycoprotein
    Yasuda, K
    Lan, LB
    Sanglard, D
    Furuya, K
    Schuetz, JD
    Schuetz, EG
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (01): : 323 - 332
  • [35] Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis
    Kaneshiro, Yasunori
    Oda, Yutaka
    Wakiri, Kentaro
    Masada, Toshiaki
    Iwaki, Hiroyoshi
    Hirota, Yoshio
    Kondo, Kyoko
    Takaoka, Kunio
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (04) : 396 - 402
  • [36] Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA
    Koch, I
    Weil, R
    Wolbold, R
    Brockmöller, J
    Hustert, E
    Burk, O
    Neussler, A
    Neuhaus, P
    Eichelbaum, M
    Zanger, U
    Wojnowski, L
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (10) : 1108 - 1114
  • [37] Metabolism of Beclomethasone Dipropionate by Cytochrome P450 3A Enzymes
    Roberts, Jessica K.
    Moore, Chad D.
    Ward, Robert M.
    Yost, Garold S.
    Reilly, Christopher A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 345 (02): : 308 - 316
  • [38] Cytochrome P450 3A polymorphisms and immunosuppressive drugs:: an update
    Anglicheau, Dany
    Legendre, Christophe
    Beaune, Philippe
    Thervet, Eric
    PHARMACOGENOMICS, 2007, 8 (07) : 835 - 849
  • [39] Effects of dexamethasone, administered for growth promoting purposes, upon the hepatic cytochrome P450 3A expression in the veal calf
    Cantiello, Michela
    Giantin, Mery
    Carletti, Monica
    Lopparelli, Rosa M.
    Capolongo, Francesca
    Lasserre, Frederic
    Bollo, Enrico
    Nebbia, Carlo
    Martin, Pascal G. P.
    Pineau, Thierry
    Dacasto, Mauro
    BIOCHEMICAL PHARMACOLOGY, 2009, 77 (03) : 451 - 463
  • [40] Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil
    Kharasch, E. D.
    Vangveravong, S.
    Buck, N.
    London, A.
    Kim, T.
    Blood, J.
    Mach, R. H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (04) : 562 - 570
12345